Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Libaoduo in Ovarian Cancer
NCT02237690Phase 1Completed
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Sep 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin + metformin in ovarian cancer (2 arms), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from 0 to last measurable observation and 1 more. Started Sep 2014; status: completed.
02
Drugs
dapagliflozin + metformin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02237690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02237690.